The relationship between methylene blue (MB) and Alzheimer's disease (AD) has recently
attracted increasing scientific attention since it has been suggested that MB may slow down …

Methylene Blue (MB), following its introduction to biology in the 19th century by Ehrlich, has
found uses in various areas of medicine and biology. At present, MB is the first line of …

Promising results have emerged from a phase II clinical trial testing methylene blue (MB) as
a potential therapeutic for Alzheimer disease (AD), where improvements in cognitive …

This paper provides the first review of the memory-enhancing and neuroprotective metabolic
mechanisms of action of methylene blue in vivo. These mechanisms have important …

Methylene blue (MB), the first synthetic drug, has a 120-year-long history of diverse
applications, both in medical treatments and as a staining reagent. In recent years there was …

The key cytopathologies in the brains of Alzheimer's disease (AD) patients include
mitochondrial dysfunction and energy hypometabolism, which are likely caused by the …

Methylene blue (MB) is a well-established drug with a long history of use, owing to its
diverse range of use and its minimal side effect profile. MB has been used classically for the …

Abnormal aggregation of β-amyloid (Aβ) peptides is a major hallmark of Alzheimer's disease
(AD). In spite of numerous attempts to prevent the β-amyloidosis, no effective drugs for …

Deposits of amyloid-β (Aβ) protein are one of the hallmarks of Alzheimer's disease (AD).
Numerous studies report that the Aβ peptide, especially in the oligomeric form, causes …

Methylene blue (MB) increases mitochondrial oxygen consumption and restores memory
retention in rats metabolically impaired by inhibition of cytochrome c oxidase. This study …